These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35184005)

  • 21. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
    Ben-Menachem E; Baulac M; Hong SB; Cleveland JM; Reichel C; Schulz AL; Wagener G; Brandt C
    Epilepsy Res; 2021 Feb; 170():106526. PubMed ID: 33461041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
    Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
    CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.
    Arnold S; Laloyaux C; Schulz AL; Elmoufti S; Yates S; Fakhoury T
    Epilepsy Res; 2020 Oct; 166():106404. PubMed ID: 32731118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis.
    Moseley BD; Dimova S; Elmoufti S; Laloyaux C; Asadi-Pooya AA
    Epilepsy Res; 2021 Oct; 176():106694. PubMed ID: 34218211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time-course of drug-related psychiatric and behavioral treatment-emergent adverse events during brivaracetam treatment in adults with focal-onset seizures.
    Meador KJ; Dimova S; Bourikas D; Elmoufti S; Floricel F; Laloyaux C; Moseley B; Nondonfaz X; Klein P
    Epilepsy Behav; 2024 Jul; 156():109844. PubMed ID: 38788664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
    Ryvlin P; Dimova S; Elmoufti S; Floricel F; Laloyaux C; Nondonfaz X; Biton V
    Epilepsia; 2022 Aug; 63(8):2024-2036. PubMed ID: 35582748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brivaracetam in the Treatment of Patients with Epilepsy-First Clinical Experiences.
    Zahnert F; Krause K; Immisch I; Habermehl L; Gorny I; Chmielewska I; Möller L; Weyand AM; Mross PM; Wagner J; Menzler K; Knake S
    Front Neurol; 2018; 9():38. PubMed ID: 29467714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: A study of 42 patients.
    Caraballo RH; Reyes G; Chacón S; Fortini PS
    Epilepsy Behav; 2024 Jan; 150():109561. PubMed ID: 38070405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brivaracetam efficacy and safety in focal epilepsy.
    Makke Y; Abou-Khalil B
    Expert Rev Neurother; 2019 Oct; 19(10):955-964. PubMed ID: 31195850
    [No Abstract]   [Full Text] [Related]  

  • 30. Rapid switching from levetiracetam to brivaracetam in pharmaco-resistant epilepsy in people with and without intellectual disabilities: a naturalistic case control study.
    Watkins LV; Dunstall H; Musicha C; Lawthom C; John K; Bright C; Richings C; Harding K; Moon S; Pape SE; Winterhalder R; Allgar V; Thomas RH; McLean B; Laugharne R; Shankar R
    J Neurol; 2023 Dec; 270(12):5889-5902. PubMed ID: 37610448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: A post hoc analysis of phase 3 trials in adults with focal seizures.
    Brandt C; Dimova S; Elmoufti S; Laloyaux C; Nondonfaz X; Klein P
    Epilepsy Behav; 2023 Jan; 138():108967. PubMed ID: 36435010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.
    Klein P; Schiemann J; Sperling MR; Whitesides J; Liang W; Stalvey T; Brandt C; Kwan P
    Epilepsia; 2015 Dec; 56(12):1890-8. PubMed ID: 26471380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus.
    Strzelczyk A; Kay L; Bauer S; Immisch I; Klein KM; Knake S; Kowski A; Kunz R; Kurlemann G; Langenbruch L; Möddel G; Müller-Schlüter K; Reif PS; Schubert-Bast S; Steinhoff BJ; Steinig I; Willems LM; von Podewils F; Rosenow F
    Epilepsia; 2018 Aug; 59(8):1549-1556. PubMed ID: 29943451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: Post-hoc analysis of a randomized, placebo-controlled trial.
    Klein P; McLachlan R; Foris K; Nondonfaz X; Elmoufti S; Dimova S; Brandt C
    Epilepsy Res; 2020 Nov; 167():106369. PubMed ID: 32717713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records.
    Villanueva V; Laloyaux C; D'Souza W; Faught E; Klein P; Reuber M; Rosenow F; Salas-Puig J; Insuga VS; Strzelczyk A; Szaflarski JP; Chinn C; Daniels T; Floricel F; Friesen D; Sendersky V; Besson H; Steinhoff BJ
    CNS Drugs; 2023 Sep; 37(9):819-835. PubMed ID: 37684497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities.
    Theochari E; Cock H; Lozsadi D; Galtrey C; Arevalo J; Mula M
    Epilepsy Behav; 2019 Jan; 90():129-131. PubMed ID: 30530134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy.
    Gillis RME; Wammes-van der Heijden EA; Schelhaas HJ; Tan IY; Festen DAM; Majoie MHJM
    Acta Neurol Belg; 2021 Jun; 121(3):677-684. PubMed ID: 32157673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, tolerability and pharmacokinetic variability of brivaracetam in adults with difficult-to-treat epilepsy.
    Svendsen T; Brodtkorb E; Linge HL; Burns ML; Johannessen SI; Nakken KO; Lossius MI; Landmark CJ
    Epilepsy Res; 2022 Jul; 183():106946. PubMed ID: 35609355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.